Abstract 353P
Background
Life-Sustaining Treatment Decision systems have been in effect since February 2018 in South Korea. These systems ensure that medically insignificant life-sustaining treatments, which are undesired by the patient, are avoided. This study was designed to develop and verify an explanatory model of terminal cancer patients’ intent related to decisions regarding discontinuing or not performing meaningless, life-sustaining treatments in South Korea.
Methods
Data were collected from April 15 to July 10 2019, via a survey using self-reported questionnaires. A total of 220 patients, with terminal cancer, were recruited. The hypothetical model was constructed using four exogenous variables—family function, knowledge on life-sustaining treatment decisions, likelihood of the treatment outcome, and treatment burden—and three endogenous variables—attitudes towards, the efficacy of, and intent regarding life-sustaining treatment decisions.
Results
The goodness-of-fit of this hypothetical model was x2=169.25, χ2/df=1.90, RMSEA=.07, RMR=0.02, GFI=.91, AGFI=.90, NFI=.97, CFI=.98, RMSEA=.06 The results demonstrated that knowledge on, attitudes towards, the efficacy of life-sustaining treatment decisions, and treatment burden all had significant and direct effects on participants’ intent regarding their treatment decisions. Family function was indirectly associated with participants’ intent regarding life-sustaining treatment decisions. These variables explained 88.8% of the total variance with respect to the intent regarding life-sustaining treatment decisions, with knowledge on these decisions being the most influential factor.
Conclusions
The results of this study suggest that, in order to improve terminal cancer patients’ intent regarding life-sustaining treatment decisions related to discontinuing or not performing meaningless life-sustaining treatments, nursing interventions should focus on enhancing their knowledge around this topic, as well as the efficacy of these choices. In particular, a patient’s family function is a crucial intervention strategy that can enhance their intent regarding life-sustaining treatment decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract